• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伴有既往严重器官受累的 SLE 患者中糖皮质激素的撤药:一项单中心回顾性分析。

Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis.

机构信息

Immuno-Rheumatology Center, St Luke's International Hospital, Chuo-ku, Japan

Immuno-Rheumatology Center, St Luke's International Hospital, Chuo-ku, Japan.

出版信息

Lupus Sci Med. 2022 Jun;9(1). doi: 10.1136/lupus-2022-000682.

DOI:10.1136/lupus-2022-000682
PMID:35654482
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9163542/
Abstract

OBJECTIVE

Long-term glucocorticoid use in SLE may have significant side effects; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups. Therefore, we evaluated the risk factors for disease flares and the flare rate on glucocorticoid tapering in patients with prior severe organ involvement.

METHODS

Data of patients with SLE with glucocorticoid tapering at our institution were retrospectively analysed. We divided the patients by the presence of prior severe organ involvement and compared flare rates after glucocorticoid discontinuation. Furthermore, we determined risk factors for flares after glucocorticoid discontinuation.

RESULTS

In total, 309 patients with SLE were screened, 73 of whom met the inclusion criteria; 49 were classified as SLE with prior severe organ involvement. No significant differences were noted in the 52-week flare rate after glucocorticoid discontinuation between patients with and without prior severe organ involvement (16.7% vs 18.2%, p=1.0). Hypocomplementaemia, elevated anti-dsDNA antibody titres more than twice the upper limit of the laboratory reference range, positive anti-Smith/anti-ribonucleoprotein antibody, and use of any immunosuppressant on the day of glucocorticoid discontinuation were negatively associated with flare-free remission.

CONCLUSIONS

Glucocorticoid discontinuation after gradual tapering can often be achieved in patients with SLE, even with prior severe organ involvement, especially when the disease is clinically and serologically stable.

摘要

目的

长期使用糖皮质激素治疗系统性红斑狼疮(SLE)可能会产生显著的副作用;然而,偶尔停用糖皮质激素会导致疾病复发。因此,我们评估了既往有严重器官受累的患者在糖皮质激素逐渐减量过程中疾病复发的风险因素和复发率。

方法

回顾性分析了我院接受糖皮质激素减量治疗的 SLE 患者的数据。我们根据是否存在既往严重器官受累将患者进行分组,并比较了糖皮质激素停药后的复发率。此外,我们还确定了糖皮质激素停药后复发的风险因素。

结果

共筛选出 309 例 SLE 患者,其中 73 例符合纳入标准;49 例被归类为既往有严重器官受累的 SLE 患者。在糖皮质激素停药后 52 周的复发率方面,有和无既往严重器官受累的患者之间无显著差异(16.7% vs 18.2%,p=1.0)。低补体血症、抗双链 DNA 抗体滴度升高超过实验室参考范围上限的两倍、抗 Smith/抗核糖核蛋白抗体阳性以及在糖皮质激素停药当天使用任何免疫抑制剂与无复发缓解相关。

结论

即使在既往有严重器官受累的情况下,SLE 患者也可以在逐渐减量的过程中经常停用糖皮质激素,尤其是在疾病处于临床和血清学稳定的情况下。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/9163542/0f59eef5d011/lupus-2022-000682f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/9163542/78033dc039a5/lupus-2022-000682f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/9163542/0f59eef5d011/lupus-2022-000682f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/9163542/78033dc039a5/lupus-2022-000682f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/639a/9163542/0f59eef5d011/lupus-2022-000682f02.jpg

相似文献

1
Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis.伴有既往严重器官受累的 SLE 患者中糖皮质激素的撤药:一项单中心回顾性分析。
Lupus Sci Med. 2022 Jun;9(1). doi: 10.1136/lupus-2022-000682.
2
Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal.在系统性红斑狼疮中撤停低剂量糖皮质激素:一个理想且可实现的目标。
Rheumatology (Oxford). 2022 Dec 23;62(1):181-189. doi: 10.1093/rheumatology/keac225.
3
Glucocorticoid discontinuation in pediatric-onset systemic lupus erythematosus: a single-center experience.糖皮质激素在儿童起病系统性红斑狼疮中的撤药:单中心经验。
Pediatr Nephrol. 2022 Sep;37(9):2131-2139. doi: 10.1007/s00467-021-05350-y. Epub 2022 Jan 26.
4
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study.在系统性红斑狼疮血清学活动但临床无活动的患者中减少糖皮质激素剂量后,出现病情复发和病情加重的风险:一项多国观察性队列研究。
Ann Rheum Dis. 2024 Jul 15;83(8):998-1005. doi: 10.1136/ard-2023-225369.
5
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.阿尼鲁单抗可降低中重度系统性红斑狼疮患者的疾病发作率。
Lupus. 2021 Jul;30(8):1254-1263. doi: 10.1177/09612033211014267. Epub 2021 May 12.
6
Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.系统性红斑狼疮病情复发的基线预测因素:来自贝利尤单抗III期试验中联合安慰剂组的数据。
Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995.
7
Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.缓解期系统性红斑狼疮患者停用免疫抑制剂后复发的患病率和预测因素。
Rheumatology (Oxford). 2020 Jul 1;59(7):1591-1598. doi: 10.1093/rheumatology/kez422.
8
Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual.低剂量糖皮质激素在系统性红斑狼疮中应停用还是继续使用?关于复发和损害积累风险的系统评价和荟萃分析。
Rheumatology (Oxford). 2021 Dec 1;60(12):5517-5526. doi: 10.1093/rheumatology/keab149.
9
Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.在实现低疾病活动度或缓解的系统性红斑狼疮患者中, flares 发生率及决定 flares 发生的因素:一项前瞻性队列研究的结果。
Lupus Sci Med. 2022 Mar;9(1). doi: 10.1136/lupus-2021-000553.
10
Clinical analysis of 61 systemic lupus erythematosus patients with intestinal pseudo-obstruction and/or ureterohydronephrosis: a retrospective observational study.61例系统性红斑狼疮合并肠道假性梗阻和/或输尿管肾盂积水患者的临床分析:一项回顾性观察研究
Medicine (Baltimore). 2015 Jan;94(4):e419. doi: 10.1097/MD.0000000000000419.

引用本文的文献

1
Glucocorticoids discontinuation in systemic lupus erythematosus: a single-centre study.系统性红斑狼疮中糖皮质激素的停用:一项单中心研究。
Rheumatol Adv Pract. 2025 Mar 31;9(2):rkaf036. doi: 10.1093/rap/rkaf036. eCollection 2025.
2
Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus.系统性红斑狼疮达标治疗策略的演变概念
Mediterr J Rheumatol. 2024 Jun 30;35(Suppl 2):328-341. doi: 10.31138/mjr.290424.eci. eCollection 2024 Jun.
3
Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations.

本文引用的文献

1
The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.贝利尤单抗治疗24周后停药,随后重新开始治疗对系统性红斑狼疮患者的影响:一项开放标签、非随机的52周研究。
Arthritis Res Ther. 2022 Feb 16;24(1):46. doi: 10.1186/s13075-022-02723-y.
2
Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis.糖皮质激素撤药后系统性红斑狼疮患者病情复发的危险因素:系统评价和荟萃分析。
Lupus Sci Med. 2022 Jan;9(1). doi: 10.1136/lupus-2021-000603.
3
Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus.
系统性红斑狼疮的治疗:一项系统文献综述,为 2023 年 EULAR 建议更新提供信息。
Ann Rheum Dis. 2024 Oct 21;83(11):1489-1501. doi: 10.1136/ard-2023-225319.
4
Saudi National Clinical Practice Guidelines for Management of Adult Systemic Lupus Erythematosus.沙特阿拉伯成人系统性红斑狼疮管理国家临床实践指南
Curr Rheumatol Rev. 2025;21(1):70-96. doi: 10.2174/0115733971275638240429063041.
5
Effect of remission, clinical remission with active serology, and glucocorticoid dosage on the pregnancy outcome of pregnant patients with systemic lupus erythematosus.缓解、伴有活动性血清学的临床缓解和糖皮质激素剂量对系统性红斑狼疮孕妇妊娠结局的影响。
Arthritis Res Ther. 2024 Mar 9;26(1):63. doi: 10.1186/s13075-024-03298-6.
6
A path to Glucocorticoid Stewardship: a critical review of clinical recommendations for the treatment of systemic lupus erythematosus.糖皮质激素管理之道:系统性红斑狼疮治疗临床推荐的批判性评价。
Rheumatology (Oxford). 2024 Jul 1;63(7):1837-1849. doi: 10.1093/rheumatology/keae041.
7
Weaning Maintenance Therapy in Lupus Nephritis: For Whom, When, and How?狼疮性肾炎的撤减维持治疗:对象、时机及方式?
Kidney Int Rep. 2023 May 22;8(8):1481-1488. doi: 10.1016/j.ekir.2023.05.012. eCollection 2023 Aug.
8
Treat-to-Target in Systemic Lupus Erythematosus: Reality or Pipe Dream.系统性红斑狼疮的达标治疗:现实还是空想。
J Clin Med. 2023 May 8;12(9):3348. doi: 10.3390/jcm12093348.
在临床静止期系统性红斑狼疮中,逐渐停用糖皮质激素是安全的。
ACR Open Rheumatol. 2021 Aug;3(8):550-557. doi: 10.1002/acr2.11267. Epub 2021 Jul 10.
4
Risk of adverse pregnancy outcomes in Japanese systemic lupus erythematosus patients with prior severe organ manifestations: A single-center retrospective analysis.日本系统性红斑狼疮患者既往有严重器官表现与不良妊娠结局风险:一项单中心回顾性分析。
Lupus. 2021 Aug;30(9):1415-1426. doi: 10.1177/09612033211016074. Epub 2021 May 20.
5
Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis.狼疮肾炎患者缓解后免疫抑制治疗的停药。
Rheumatology (Oxford). 2022 Feb 2;61(2):688-695. doi: 10.1093/rheumatology/keab373.
6
Effectiveness and safety of mizoribine for the treatment of IgG4-related disease: a retrospective cohort study.米佐米滨治疗 IgG4 相关疾病的疗效和安全性:一项回顾性队列研究。
Rheumatology (Oxford). 2021 Dec 1;60(12):5697-5704. doi: 10.1093/rheumatology/keab235.
7
New insights into the role of antinuclear antibodies in systemic lupus erythematosus.抗核抗体在系统性红斑狼疮中的作用的新认识。
Nat Rev Rheumatol. 2020 Oct;16(10):565-579. doi: 10.1038/s41584-020-0480-7. Epub 2020 Sep 3.
8
Potential and prognostic factor for belimumab-free remission in patients with systemic lupus erythematosus: a single-center retrospective analysis.系统性红斑狼疮患者无贝利尤单抗缓解的潜在因素及预后因素:一项单中心回顾性分析
Clin Rheumatol. 2020 Dec;39(12):3653-3659. doi: 10.1007/s10067-020-05052-0. Epub 2020 Jun 24.
9
2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.2020 年美国风湿病学会风湿病和肌肉骨骼疾病生殖健康管理指南。
Arthritis Rheumatol. 2020 Apr;72(4):529-556. doi: 10.1002/art.41191. Epub 2020 Feb 23.
10
Validation of the 2019 ACR/EULAR classification criteria of systemic lupus erythematosus in 100 Japanese patients: a real-world setting analysis.验证 2019 年 ACR/EULAR 系统性红斑狼疮分类标准在 100 例日本患者中的应用:真实世界设定分析。
Clin Rheumatol. 2020 Jun;39(6):1823-1827. doi: 10.1007/s10067-019-04848-z. Epub 2020 Feb 12.